SKYSONA

This brand name is authorized in Estonia, France, Lithuania, Poland.

Active ingredients

The drug SKYSONA contains one active pharmaceutical ingredient (API):

1	Elivaldogene autotemcel UNII KUM75TD6SG - ELIVALDOGENE AUTOTEMCEL
	Elivaldogene autotemcel is indicated for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an ABCD1 genetic mutation. Elivaldogene autotemcel adds functional copies of the ABCD1 cDNA into patients' HSCs through transduction of autologous CD34+ cells with Lenti-D LVV. Following successful engraftment with genetically modified cells, the expression of ALDP is expected to be life-long.
	Read more about Elivaldogene autotemcel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SKYSONA Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07	Other nervous system drugs	N Nervous system
Discover more medicines within N07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1858596
FR	Base de données publique des médicaments	65249832
LT	Valstybinė vaistų kontrolės tarnyba	1093082
PL	Rejestru Produktów Leczniczych	100456917